Hope arrived fast. So did the confusion.
The FDA’s approval of a new Alzheimer’s treatment has families across the country asking the same urgent question: how do we actually get it?
Why this approval feels like a turning point
When the FDA approved Kisunla, the brand name for donanemab-azbt, on July 2, 2024, it marked a major moment in Alzheimer’s care because the drug is aimed at the biology of the disease, not just its symptoms. The agency said treatment should be started in people with mild cognitive impairment or mild dementia stage Alzheimer’s disease, which is the group studied in the clinical trials. That narrow indication matters, because many families hear “Alzheimer’s drug” and understandably assume it applies across all stages of the disease. According to the FDA, it does not.
Kisunla joins a small and closely watched class of anti-amyloid antibody therapies. Before it, Leqembi received traditional FDA approval on July 6, 2023, after a confirmatory trial verified clinical benefit, becoming the first amyloid beta-directed antibody to move from accelerated approval to traditional approval for Alzheimer’s disease. In other words, Kisunla is not the first disease-targeting Alzheimer’s drug to reach the market, but it is the first newly approved entrant in this category in about a year, and the first fresh approval after a long period with little movement.
That distinction helps explain the wave of public interest. Families have spent years hearing about stalled research, disputed approvals, and promising but unfinished data. Now they are hearing a more concrete message: there is a drug with FDA approval for early symptomatic Alzheimer’s, backed by a large study of 1,736 patients. In that trial, patients had confirmed amyloid pathology and received an IV infusion every four weeks, with dosing potentially stopped after scans showed amyloid had been sufficiently reduced.
The emotional response is easy to understand. Alzheimer’s is progressive, irreversible, and devastating, affecting more than 6.5 million Americans, according to the FDA. Families often experience diagnosis as a race against time, so any therapy that may slow decline becomes urgent immediately. But urgency can blur the reality that this is not a cure, not a treatment for every patient, and not something most people can start next week without a lengthy workup.
What the drug actually does, and what it does not do
Kisunla is designed to clear amyloid plaque in the brain, one of the central biological hallmarks of Alzheimer’s disease. The FDA’s approval was based on the TRAILBLAZER-ALZ 2 study, a phase 3 trial that tested the drug in people with early symptomatic Alzheimer’s who had both amyloid and tau pathology. The study found a statistically significant slowing of clinical progression at 76 weeks, including better results than placebo on the integrated Alzheimer Disease Rating Scale, a measure that blends cognition and daily function.
The numbers are meaningful, but they need careful interpretation. In the combined study population, the least-squares mean change on the iADRS was −10.2 with donanemab versus −13.1 with placebo, a difference of 2.92 points. In the lower and medium tau group, the difference was 3.25 points. Researchers also reported that the drug delayed disease progression by several months on key measures and lowered risk of progression over the 18-month trial period. That is why many specialists describe the benefit as clinically real, yet modest rather than transformative.
This is the part families need explained clearly. Kisunla does not restore lost memory. It does not stop Alzheimer’s from progressing forever. It does not work like an antibiotic, where a course of treatment eliminates the illness. Instead, the best current reading of the evidence is that, in appropriately selected patients early in the disease, it can slow decline. For some households, a slower decline may mean extra months of independence, steadier daily routines, or more time while a loved one can still participate in decisions and relationships.
It is also important to understand how Kisunla differs from older Alzheimer’s medicines. Traditional drugs such as donepezil or memantine are used to manage symptoms related to memory and cognition. Anti-amyloid antibodies are different: they target a disease pathway. That scientific shift is why the approval drew such intense attention from clinicians, Wall Street, advocacy groups, and patients. But targeting the disease process also brings more complicated eligibility rules, more monitoring, and more serious risk discussions than many families expect at the start.
Why getting the drug is harder than asking for a prescription
For most families, the first barrier is simply qualifying. The FDA-approved use is for patients in the mild cognitive impairment or mild dementia stage of Alzheimer’s disease, and the diagnosis must be supported by evidence of amyloid pathology. That usually means specialist evaluation plus amyloid PET imaging or another accepted biomarker-based confirmation process. A patient with more advanced dementia, unclear diagnosis, or another major neurological issue may not be an appropriate candidate even if family members are eager to move quickly.
The next barrier is infrastructure. Kisunla is given as an intravenous infusion every four weeks, not as a pill picked up at the local pharmacy. Patients need access to a clinician comfortable prescribing it, an infusion center able to administer it, and a system that can coordinate brain imaging before and during treatment. The prescribing information says patients should have a recent baseline MRI before starting, then MRIs before the 2nd, 3rd, 4th, and 7th infusions, with additional imaging if symptoms suggest treatment-related complications. That alone can slow the timeline in parts of the country where neurology appointments and MRI slots are already backlogged.
Insurance and Medicare add another layer. CMS said broader Medicare coverage became available for Leqembi after traditional approval, but patients needed to be enrolled in Medicare, have mild cognitive impairment or mild Alzheimer’s disease dementia with documented beta-amyloid plaque, and have a physician participating in a qualifying registry. CMS also noted that people in Original Medicare generally face the standard 20% coinsurance of the Medicare-approved amount after meeting the Part B deductible. While Kisunla is a different product, this framework showed families what access to this class of drug can look like in practice: coverage is possible, but it comes with conditions, paperwork, and out-of-pocket exposure.
That is why the phrase “How do we get it?” really means several different questions. Can we prove the diagnosis? Is there amyloid confirmation? Is there a prescribing neurologist nearby? Can the patient tolerate repeated MRIs and infusion visits? What will secondary insurance cover? These are healthcare system questions as much as medical ones. For families in rural areas or for patients already struggling with transportation and frailty, the logistics may be as decisive as the science.
The safety conversation families cannot afford to skip
The biggest medical concern surrounding Kisunla is ARIA, short for amyloid-related imaging abnormalities. The FDA-approved label carries a boxed warning for ARIA, which can include brain swelling and small areas of bleeding. The agency recommends heightened vigilance during the first 24 weeks of treatment, and the label says monitoring MRIs are required because ARIA may occur early and may not always cause obvious symptoms at first.
In the prescribing information, symptomatic ARIA occurred in 6% of Kisunla-treated patients in the key study. Including asymptomatic radiographic events, ARIA was seen in 36% of treated patients versus 14% on placebo. ARIA-E, the edema or swelling form, occurred in 24% of treated patients compared with 2% on placebo, while ARIA-H, which includes microhemorrhage and superficial siderosis, occurred in 31% versus 13%. The label also reports intracerebral hemorrhage greater than 1 cm in 0.5% of treated patients, and notes that fatal hemorrhage events have been observed.
Risk is not the same for every patient. The label states that people who are ApoE ε4 homozygotes face a higher incidence of ARIA, including symptomatic and serious ARIA, than heterozygotes and noncarriers. About 15% of Alzheimer’s patients fall into that homozygous group, according to the label, and the prescribing information says testing should be performed before starting treatment to help inform risk discussions. That does not automatically rule treatment out, but it does make genetic counseling and informed consent far more important than families may expect.
None of this means the drug should be feared or dismissed. It means the treatment decision has to be made with clear eyes. In practice, the right conversation is not “Is this drug good or bad?” but “For this specific patient, at this stage of disease, with this MRI history, this genetic profile, and this care support, does the potential slowing of decline outweigh the burden and risk?” That is a much harder question, but it is the honest one, and increasingly, specialists are trying to guide families toward exactly that frame.
What families should do next if they want to pursue treatment
The best first step is not calling an infusion center. It is asking for a careful memory evaluation, ideally with a neurologist, geriatrician, or cognitive disorders specialist who regularly treats early Alzheimer’s disease. Families should be prepared for the possibility that symptoms may not actually be Alzheimer’s, or that the disease may be beyond the mild cognitive impairment or mild dementia stage studied in the trial. A strong workup usually includes cognitive testing, medical history, medication review, lab work, brain imaging, and confirmation of amyloid pathology before the conversation about Kisunla becomes concrete.
Once a patient appears eligible, the next discussion should focus on the practical pathway. Ask what testing is still needed, whether ApoE ε4 testing is recommended, where infusions would occur, how often MRIs can realistically be scheduled, and what symptoms should trigger an emergency call. Because ARIA symptoms can resemble stroke symptoms, the FDA label advises immediate medical attention for warning signs such as headache, confusion, vision changes, weakness, or seizures. Families should also ask who will coordinate care if the patient sees multiple clinicians across different systems.
Cost questions belong at the start, not the end. CMS’s Leqembi framework made clear that broader Medicare access can still leave patients responsible for coinsurance and ancillary costs, especially imaging and infusion-related logistics. Private insurance policies may vary, and hospital systems differ in how quickly they build capacity for new specialty drugs. A treatment that looks available in headlines can still be hard to access in real life if a region lacks trained prescribers, infusion space, or reimbursement clarity.
The larger truth is that this approval changes the Alzheimer’s landscape, but it does not simplify it. Kisunla represents genuine scientific progress and a serious option for some patients with early disease. It also demands more diagnosis precision, more monitoring, and more family involvement than many other chronic-disease treatments. For families asking how to get it, the answer is both encouraging and sobering: start early, get evaluated carefully, confirm eligibility, prepare for monitoring, and expect the process to be a medical journey rather than a quick prescription.